Vectibix Dosage/Direction for Use

Panitumumab (Vectibix) treatment should be supervised by a physician experienced in the use of anti-cancer therapy. Evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with Panitumumab (Vectibix). Mutational status should be determined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) mutations.
Posology: The recommended dose of Panitumumab (Vectibix) is 6 mg/kg of bodyweight given once every two weeks.
Modification of the dose of Panitumumab (Vectibix) may be necessary in cases of severe (≥ grade 3) dermatological reactions as follows: (see Table 6.)

Click on icon to see table/diagram/image

Special populations: The safety and efficacy of Panitumumab (Vectibix) have not been studied in patients with renal or hepatic impairment.
There is no clinical data to support dose adjustments in the elderly.
Paediatric population: There is no relevant use of Panitumumab (Vectibix) in the paediatric population in the indication treatment of colorectal cancer.
Method of administration: Panitumumab (Vectibix) must be administered as an intravenous infusion via an infusion pump.
Prior to infusion, Panitumumab (Vectibix) should be diluted in sodium chloride 9 mg/mL (0.9%) solution for injection to a final concentration not to exceed 10 mg/mL (for preparation instructions see Special precautions for disposal and other handling under Cautions for Usage).
Panitumumab (Vectibix) must be administered using a low protein binding 0.2 or 0.22 micrometre in-line filter, through a peripheral line or indwelling catheter. The recommended infusion time is approximately 60 minutes. If the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes. Doses higher than 1,000 mg should be infused over approximately 90 minutes (for handling instructions, see Special precautions for disposal and other handling under Cautions for Usage).
The infusion line should be flushed with sodium chloride solution before and after Panitumumab (Vectibix) administration to avoid mixing with other medicinal products or intravenous solutions.
A reduction in the rate of infusion of Panitumumab (Vectibix) may be necessary in cases of infusion-related reactions (see Precautions).
Panitumumab (Vectibix) must not be administered as an intravenous push or bolus.
For instructions on dilution of the medicinal product before administration, see Special precautions for disposal and other handling under Cautions of Usage.